Search for 'an:"303" and au:Iglesias Docampo, Lara'

Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.

By Rodríguez Garzotto, Analía | Díaz García, C. Vanesa | Agudo López, Alba | Prieto García, Elena | Ponce Aix, Santiago | López Martín, José Antonio | Paz-Ares Rodríguez, Luis | Iglesias Docampo, Lara | Agulló Ortuño, María Teresa. Medical oncology (Northwood, London, England), 2016 . 33(10):105. , Formato Vancouver: Rodríguez Garzotto A, Díaz García CV, Agudo López A, Prieto García E, Ponce S, López Martín JA et al. Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer. Med Oncol. 2016 Oct;33(10):105.

Place Hold on Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.

Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer.

By Díaz García, C. Vanesa | Agudo López, Alba | Pérez, Carlos | Prieto García, Elena | Iglesias Docampo, Lara | Ponce Aix, Santiago | Rodríguez Garzotto, Analía | Rodríguez Peralto, José Luis | Cortés-Funes Castro, Hernán | López Martín, José Antonio | Agulló Ortuño, María Teresa. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015 . 36(2):1199-206. , Formato Vancouver: Díaz García CV, Agudo López A, Pérez C, Prieto García E, Iglesias L, Ponce S et al. Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer. Tumour Biol. 2015 Feb;36(2):1199-206.

Place Hold on Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer.

Manejo de la enfermedad tromboembólica venosa en pacientes oncológicos: guías de práctica clínica española. Consenso SEACV-SEOM,

By Iglesias Docampo, Lara. Medicina clínica, 2015 . 144 Suppl 1:3-15. , Formato Vancouver: Olmos VP, Ramos Gallo MJ, Rebollo MA, Ortega DB, Docampo LI, Romera Villegas A et al; Sociedad Española de Oncología Médica (SEOM); Sociedad Española de Angiología y Cirugía Vascular (SEACV). Manejo de la enfermedad tromboembólica venosa en pacientes oncológicos: guías de práctica clínica española. Consenso SEACV-SEOM. Med Clin (Barc). 2015 Jan;144 Suppl 1:3-15.

Place Hold on Manejo de la enfermedad tromboembólica venosa en pacientes oncológicos: guías de práctica clínica española. Consenso SEACV-SEOM,

The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects.

By Zugazagoitia, Jon | Enguita Valls, Ana Belén | Núñez Sobrino, Juan Antonio | Iglesias Docampo, Lara | Ponce Aix, Santiago. Journal of thoracic disease, 2014 . 6(Suppl 5):S526-36. , Formato Vancouver: Zugazagoitia J, Enguita AB, Nuñez JA, Iglesias L, Ponce S. The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects. J Thorac Dis. 2014 Oct;6(Suppl 5):S526-36.

Place Hold on The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects.

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.

By Iglesias Docampo, Lara. The Lancet. Oncology, 2014 . 15(12):1369-78. , Formato Vancouver: Ramalingam SS, Jänne PA, Mok T, O'Byrne K, Boyer MJ, Von Pawel J, Pluzanski A, Shtivelband M, Docampo LI, Bennouna J, Zhang H, Liang JQ, Doherty JP, Taylor I, Mather CB, Goldberg Z, O'Connell J, Paz-Ares L. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1369-78.

Place Hold on Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.

DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification.

By Agudo López, Alba | Agulló Ortuño, María Teresa | Cortés-Funes Castro, Hernán | Cortijo, Ana | Díaz García, C. Vanesa | Iglesias Docampo, Lara | López Martín, José Antonio | Martínez Villanueva, Miriam | Pérez, Carlos | Rodríguez Peralto, José Luis. Carcinogenesis, 2013 . 34(5):1031-8. , Formato Vancouver: Díaz-García CV, Agudo-López A, Pérez C, López-Martín JA, Rodríguez-Peralto JL, de Castro J et al. DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification. Carcinogenesis. 2013 May;34(5):1031-8.

Place Hold on DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification.

Experience with vandetanib in medullary thyroid cancer

By Caro Teller, José Manuel | Cortijo Cascajares, Susana | Escribano Valenciano, Irene | Serrano Garrote, Olga | Sepúlveda Sánchez, Juan Manuel | Iglesias Docampo, Lara | Ferrari Piquero, José Miguel. European Journal of Clinical Pharmacy, 2014 . 16(6):451-453. , Formato Vancouver: Caro Teller JM, Cortijo Cascajares S, Escribano Valenciano I, Serrano Garrote O, Sepúlveda Sánchez JM, Iglesias Docampo L, et al. Experience with vandetanib in medullary thyroid cancer. Eur J Clin Pharm. 2014;16(6):451-3

Place Hold on Experience with vandetanib in medullary thyroid cancer

Sorafenib in metastatic thyroid cancer.

By Iglesias Docampo, Lara. Endocrine Related Cancer, 2012 . 19(2):209-16. , Formato Vancouver: Capdevila J, Iglesias L, Halperín I, Segura A, Martínez-Trufero J, Vaz MÁ, et al. Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer. 2012 Apr 10;19(2):209-16.

Place Hold on Sorafenib in metastatic thyroid cancer.